2,109 randomized oncology trials map continuous, meager improvements in progression-free and overall survival over 50 years

Austin J. Parish; Ioana Alina Cristea; Ewoud Schuit; John P A Ioannidis

doi:10.1016/j.jclinepi.2022.06.013

Article2024

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Meletios A Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey E. Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar

Article2017

Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Meletios A Dimopoulos, Pieter Sonneveld, Hareth Nahi, Shaji Kumar, Mahmoud Hashim, Margarita Kulakova, Marta Duran, Bart Heeg, Annette Lam, Lindsay Dearden

Article2022

Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression free and overall survival

Stavroula Α. Paschou, Michalis Liontos, Evangelos Eleftherakis-Papaiakovou, Katerina Stefanaki, Christos Markellos, Konstantinos Koutsoukos, Flora Zagouri, Θεοδώρα Ψαλτοπούλου, Meletios A Dimopoulos

Article2021

Oncological Patients with Endocrine Complications after Immunotherapy with Checkpoint Inhibitors Present Longer Progression Free and Overall Survival

Stavroula Α. Paschou, Michalis Liontos, Evangelos Eleftherakis-Papaiakovou, Katerina Stefanaki, Christos Markellos, Konstantinos Koutsoukos, Flora Zagouri, Θεοδώρα Ψαλτοπούλου, Meletios A Dimopoulos

Article2022

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival

Stavroula Α. Paschou, Michalis Liontos, Evangelos Eleftherakis-Papaiakovou, Katerina Stefanaki, Christos Markellos, Konstantinos Koutsoukos, Flora Zagouri, Θεοδώρα Ψαλτοπούλου, Meletios A Dimopoulos

2,109 randomized oncology trials map continuous, meager improvements in progression-free and overall survival over 50 years

Discussion(0)

Related publications

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression free and overall survival

Oncological Patients with Endocrine Complications after Immunotherapy with Checkpoint Inhibitors Present Longer Progression Free and Overall Survival

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival